drugset
Drugs / PERSERIS
last change Sep 2024 re-read 2 minutes ago

PERSERIS

also known as RBP-7000
Developed for
schizophrenia
Investigated by
Indivior Inc.

Trials 1 · a red edge is where a trial was stopped

today NCT03978832 · Ph 4
2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT03978832 Jun 2019 → May 2020 schizophrenia Indivior Inc. Completed No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2024-09-21 Teva Branded Pharmaceutical Products R&D, Inc. New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000) tevapharm.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as PERSERIS ClinicalTrials.gov intervention name — accepted as the source's own label NCT03978832 ↗
Known as RBP-7000 “RBP-7000 (PERSERIS®) is a monthly risperidone formulation (90 or 120 mg) for the treatment of schizophrenia administered by subcutaneous abdominal injection.” PMID 38388986 ↗ Feb 2024
Route Subcutaneous “PERSERIS is an extended-release subcutaneous (SC) injectable suspension administered monthly for the treatment of schizophrenia in adults.” NCT03978832 ↗